Comments
Shasun Pharmaceuticals and Switzerland-based biopharmaceutical group Debiopharm Group have entered into a licensing agreement for the manufacture and commercialisation of a drug for treating memory deficit and Alzheimer’s diseases.
According to the agreement, Shasun can use the Debiopharm technology for manufacture of the Huperzine-A drug and commercialise it in pharmaceutical and nutraceutical markets.
The technology involves a 10-stage chemical synthesis process. The synthesis is a result of a joint collaboration between Shasun’s research centres in Chennai and the UK, said a press release.
Mauvernay, President and Founder, Debiopharm Group, said: “Clinical studies have demonstrated the drug to enable significant improvement in both memory deficit and cognitive performance and we are excited to have the opportunity to add value to this technology.”
Michel Spagnol, President, Shasun Pharmaceuticals, said: “We are very proud of this achievement, resulting from a very close collaboration with Debiopharm. It underlines our commitment to delivering cutting-edge science in all our processes through our global research and development network.”
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.